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SUMMARY The aim of the study was to investigate the efficacy, 
safety and compliance of 500 mg azithromycin thrice weekly for 
12 weeks in moderate inflammatory acne vulgaris. An open-la-
bel, noncomparative study was carried out for 12 weeks at De-
partment of Dermatology and Plastic Surgery, La Sapienza Uni-
versity in Rome. Fifty-seven patients (20 male and 37 female) 
between 13 and 41 years of age, affected by moderate papulo-
pustular and nodular acne vulgaris, were enrolled in the study. 
Azithromycin 500 mg was administered orally thrice weekly 
for 12 weeks. Patients were examined at baseline, 4 weeks, 8 
weeks and 12 weeks (completion of treatment), evaluating both 
clinical (Global Acne Grading System, GAGS) and quality of life 
(Acne Quality of Life Questionnaire, AQoL) improvements. Forty-
six patients completed the study and showed significant improve-
ment. Six patients interrupted their treatment, while five patients 
did not complete the study for unknown reasons. Side effects 
(diarrhea and abdominal pain) were recorded in eight patients. 
Azithromycin, 500 mg thrice weekly for 12 weeks, is a safe and 
effective treatment for moderate acne vulgaris with excellent pa-
tient compliance.
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INTRodUCTIoN
 Acne is an inflammatory cutaneous disorder 
involving the pilosebaceous unit with a multi-fac-
torial pathogenesis. According to epidemiologi-
cal studies, acne is a common condition affecting 
80% of young people between 12 and 18 years of 
age as well as 5% of females and 1% of males in 
adulthood. It is also the most common reason for 
consultation in private dermatology practices (1). 
The most notable pathophysiological factors that 
influence the development of acne are sebaceous 
gland hyperplasia with seborrhea, abnormal des-
quamation of sebaceous follicle epithelium (com-
edogenesis), increased bacterial colonization of 
the follicle (Propionibacterium acnes), and inflam-
matory and immune reactions (1-3). 
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 Acneic lesions often leave lifelong scars and 
hyperpigmentations. Both scarring and hyperpig-
mentation may result in substantial disfigurement 
that can have an effect on the patients’ self-image, 
impacting considerably on their emotional health 
and quality of life (4). Comparisons with other 
chronic illnesses have shown that acne patients 
have levels of social, psychological and emotion-
al impairments that are similar to those reported 
by patients with more serious diseases such as 
asthma, epilepsy, diabetes, back pain or arthritis 
(5). It is necessary to find an effective treatment to 
reverse this social and psychological disability. A 
typical aspect of acne is the lesional pleomorphism 
with different lesions simultaneously present in 
the same patient. For this reason, acne may be 
present in a wide variety of clinical forms depend-
ing on the type, number and severity of the pre-
dominant lesion. There are many classifications 
of acne; if we consider the severity of symptoms 
and the type of predominant lesions, acne may be 
mild – comedonal and papulopustular with few le-
sions; moderate – papulopustular with numerous 
lesions and nodular with small nodules; and se-
vere – nodular-conglobate (some authors would 
also add a very severe category). The pathophysi-
ological features of acne suggest that combination 
therapy is the best choice and it should be utilized 
as early as possible to simultaneously attack two 
or more pathogenic factors, as recommended by a 
recent therapeutic algorithm (2,6,7). Topical thera-
pies include comedolytic agents such as topical 
retinoids, alpha hydroxy-acids, salicylic acid and 
azelaic acid, or antibacterial agents such as ben-
zoyl peroxide and topical antibiotics. Systemic 
treatments for acne vulgaris include oral antibiot-
ics, hormonal agents and isotretinoin (2,6,7). 
 Oral antibiotics continue to play an integral role 
in the management of acne and should be used in 
moderate-to-severe inflammatory forms. In addi-
tion to their indirect anti-inflammatory action, the 
interference with the growth and metabolism of 
Propionibacterium acnes, thought to trigger the in-
flammatory response in acne, oral antibiotics also 
have a direct anti-inflammatory action, inhibiting 
neutrophil chemotaxis, cytokine production and 
macrophage functions. In acne treatment antibi-
otics are typically administered for a prolonged 
period of time, from a minimum of 6-8 weeks to a 
maximum of 12-18 weeks but should not be used 
as monotherapy (1,6,7). In fact, in order to reduce 
the risk of bacterial resistance, it is recommended 
to use topical retinoids in association with benzoyl 
peroxide during and between antibiotic courses. 
The preferred agents of choice include tetracy-
clines and macrolides (1,6,7). 
 Azithromycin is an orally administered mac-
rolide, structurally related to erythromycin, but 
with an enhanced spectrum of activity against 
gram-positive and gram-negative pathogens as 
well as a longer serum and tissue half-life, allow-
ing for once-daily dosing. In addition to its use in 
the treatment of lower and upper respiratory tract 
infections (acute exacerbations of chronic bron-
chitis and pneumonia) or odontogenic infections, 
azithromycin is also indicated for skin and soft 
tissue infections. Good results have also recently 
been reported in the literature regarding its use in 
the treatment of inflammatory acne vulgaris.
 The pharmacokinetic profile of azithromycin 
is characterized by a rapid and extensive uptake 
from the circulation into the intracellular compart-
ments, followed by slow release (8). These factors 
allow for a single dose regimen and the potential 
for increased compliance. Azithromycin is rapidly 
absorbed from the small intestine and peak serum 
concentration is reached within 2-3 hours after in-
gestion (9). Patient age has minimal effect on the 
absorption of azithromycin, while food and antac-
ids decrease the peak serum concentration but 
do not influence the overall absorption of the drug 
(9,10). 
 Upon absorption, azithromycin is redistributed 
from the circulation and delivered by phagocytes 
to the foci of infection via the activation of che-
motaxis (11,12). Accumulation of macrolides, and 
in particular azithromycin, is inflammation-depen-
dent: phagocytic cells such as macrophages and 
polymorphonuclear leukocytes (PMNs) actively 
take up azithromycin, producing intracellular con-
centrations up to 200 times those found in serum 
(12). The drug concentrates intracellularly in lyso-
somes. Although concentration in host cells is a 
feature of the macrolides as a class, the intracellu-
lar concentrations that can be achieved by azithro-
mycin are much higher than the levels attainable 
by other related compounds (12). The presence of 
bacteria at the infection site stimulates the release 
of azithromycin from phagocytes (13). In addition, 
the subsequent fusion of lysosomes (containing 
high concentrations of azithromycin) with phago-
somes exposes microorganisms to azithromycin 
(13). Moreover, fibroblasts may act as a tissue res-
ervoir of azithromycin, and the drug may then be 
either slowly released from these cells at local sites 
of infection, or transferred to phagocytes, which 
can then transport it to the infected tissues (14). 
The most common side effects in adults receiving 
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a multiple or single-dose regimen of azithromycin 
are related mainly to the gastrointestinal system, 
and include diarrhea/loose stools, nausea/vomit-
ing, abdominal pain and dyspepsia.
 This study was carried out in order to estimate 
the efficacy of azithromycin in the treatment of 
moderate inflammatory acne vulgaris (papulopus-
tular and nodular). Moreover, the aim of this study 
was to assess the patients’ perception of the dis-
ease, the impact of acne on their emotional health 
and quality of life and, finally, the possible effects 
of successful treatment on these aspects of life.
MATeRIALS ANd MeTHodS
 In order to estimate the efficacy, tolerance and 
compliance of systemic azithromycin in the treat-
ment of moderate inflammatory acne vulgaris, an 
open-label, non-comparative study was carried 
out for 12 weeks at the Department of Dermatol-
ogy and Plastic Surgery, La Sapienza University 
in Rome. Fifty-seven Caucasian patients (20 male 
and 37 female) aged 13-41 and affected by mod-
erate acne, defined as a score of 1 to 30 on the 
Global Acne Grading System (GAGS) scale (15), 
were enrolled and examined: 55 patients were af-
fected by moderate papulopustular acne and two 
by moderate nodular acne. All patients were given 
azithromycin, 500 mg, orally thrice weekly for 12 
weeks. Patients were excluded if they met any of 
the following criteria: renal disease, hypersensitiv-
ity to azithromycin, or a history of regional enteri-
tis, ulcerative colitis, or antibiotic-associated coli-
tis. Also excluded were patients who were unwill-
ing or unable to undertake acne therapy. Together 
with systemic azithromycin, patients were given 
0.1% topical adapalene (gel or cream) to apply to 
the affected areas of the face and trunk once daily 
in the evening, and benzoyl peroxide (gel) to ap-
ply to inflammatory lesions of the face and trunk 
once daily in the morning after the skin had been 
cleansed and dried. 
 Patients were examined at baseline, 4 weeks, 
8 weeks and 12 weeks (completion of treatment), 
in order to evaluate their clinical improvement 
and to measure the psychological effects of acne. 
Clinical improvement was assessed using a clini-
cal evaluation system (GAGS). The GAGS global 
score is calculated by rating six different locations 
(forehead, right cheek, left cheek, nose, chin and 
chest/upper back) as 0 (no lesions), 1 (≥1 come-
do), 2 (≥1 papule), 3 (≥1 pustule) or 4 (≥1 nodule), 
and then multiplying each rating by a factor that 
is specific to the area. Factors are based on the 
surface area and distribution/density of piloseba-
ceous units. Global score is the sum of all six loca-
tion scores and global grade is defined according 
to the global score (Table 1). Global score (15) 
correlated with the severity of acne (15).  
 Although many clinical measures are accept-
able for assessing acne severity, patient percep-
tion of the disease may include factors other than 
the severity and number of lesions. As facial acne 
is highly visible and carries a certain degree of so-
cial negativity, it has been hypothesized that even 
mild acne can decrease the person’s self-confi-
dence, body image, and willingness to be seen 
in public and social interactions. To assess the 
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effects of acne on patient quality of life, individu-
al points of view and the impact of treatment on 
quality of life parameters, each participant was 
asked to complete an acne-specific questionnaire 
(Acne Quality of Life Questionnaire AQoL) (16) 
upon entering the study and during follow up. This 
questionnaire, self-administered to the patients, 
contains 19 questions, each referring to the past 
week, organized into four domains (self-percep-
tion, role-social, role-emotional, acne symptoms). 
AQoL domain scores are calculated by summing 
all items within a domain. Responses to all items 
are on a scale from 0 (“extremely”or “extensive”) 
to 6 (“not at all”or “none”) with each item within a 
domain weighed equally. For all domains, higher 
scores reflect better AQoL (16).
 The GAGS and AQoL values were used to de-
tect clinical and psychological improvement during 
treatment.
 Statistical analysis
 We calculated means (standard deviations) of 
quantitative variables (GAGS and AQoL levels). 
Differences between two periods were estimated 
using the nonparametric test for paired data (Wil-
coxon test). Analysis of variance (ANOVA) with re-
peat measurements (F test) was used in order to 
verify differences in GAGS and AQoL levels over 
time. Spearman correlation coefficient (rho) was 
used to asses the correlation between GAGS and 
AQoL levels for each time period. The significance 
level was set at p<0.05.
ReSULTS
 Forty-six of 57 patients (19 male and 27 female, 
mean 17.8±2.9 and 20.8±6.7) completed the study 
and showed significant improvement of acneic le-
sions. Eight patients complained of gastrointes-
tinal side effects (abdominal pain and diarrhea): 
six of them interrupted their azithromycin regime 
before the end of treatment, three during the first 
month of therapy, and another three during the 
second month. Another five patients discontinued 
treatment during the first month for unknown rea-
sons. 
 Efficacy was defined as percentage reduc-
tion of lesions. Patients enrolled and followed-up 
showed a reduction in lesions from treatment week 
4 onwards. This reduction was evaluated through 
an objective criterion (GAGS). In fact, at the end 
of treatment the GAGS average score was lower 
(GAGS: 9.15) than the scores obtained before ther-
apy (GAGSpre: 22.2), at 4 weeks (GAGS:16.28) 
and at 8 weeks (GAGS:12.58) of  therapy. 
 The ANOVA for repeat measurement revealed 
a significant difference for GAGS levels over time 
(F test=5.754; p=0.002). In this case there were no 
sex (p=0.935) or age (p=0.335) differences. Com-
parison of GAGS levels before treatment yielded 
a highly statistically significant difference against 
each follow up period (Wilcoxon test: p<0.001) 
(Fig. 1).
 The reduction of acneic lesions, both inflamma-
tory and non-inflammatory, was associated with 
lower psychological and emotional impairment, as 
demonstrated by AQoL questionnaire scores ob-
tained before treatment and at 4, 8 and 12 weeks. 
More specifically, the average score at the end 
of therapy (AQoL 91.21) was higher than before 
therapy (AQoL 69.34), at 4 weeks (AQoL 81.78) 
and at 8 weeks (AQoL 83.52). 
 ANOVA for repeat measures revealed a sig-
nificant difference of AQoL levels over time (F 
test=31.040; p<0.0001); once again there were 
no sex (p=0.267) and age (p=0.076) differenc-
es. Comparison of AQoL levels before treatment 
showed a highly statistically significant difference 
against each period of follow up (Wilcoxon test: 
p<0.001) (Fig. 2).
 Comparison of the average trend for the two 
independent parameters, GAGS and AQoL, sug-
gested an association between the progressive 
reduction of GAGS, relating to clinical improve-
ment, and the increase in AQoL values, relating to 
improvement in the quality of life.
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Figure 1. Average Global Acne Grading  System 
(GAGS) in 46 patients
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 Spearman correlation coefficients between 
GAGS and AQoL over time are shown in Table 2. 
It is evident that there is no strong correlation be-
tween these two variables before and after treat-
ment, (p>0.10).
coadministered with local therapy, adapalene 
0.1% (in the morning) and benzoyl peroxide 5% 
(in the evening). Both clinical (GAGS) and quality 
of life (AQoL) improvements were evident from the 
beginning of week 4 of therapy and continued to 
be evident at weeks 8 and 12 of treatment. 
 The results recorded at the end of the study 
demonstrate that azithromycin, 500 mg, adminis-
tered orally thrice weekly for 12 weeks, is a good 
and safe therapeutic choice in the treatment of 
moderate inflammatory acne. The clinical improve-
ment obtained from week 8 to week 12 suggests 
that systemic antibiotics in acne therapy have to 
be taken for 3 months in order to achieve the best 
therapeutic results and to decrease the risk of bac-
terial resistance. The mode of administration, good 
compliance, enhanced spectrum of activity against 
gram-positive and gram-negative pathogens, and 
longer serum and tissue half-lives make azithro-
mycin an important adjunct for the dermatologist in 
the treatment of gram-positive and gram-negative 
infections. Up to now, cases of Propionibacterium 
acnes resistance to azithromycin have never been 
reported. Moreover, this antibiotic was well toler-
ated by the great majority of patients with only six 
of 57 (10.5%) patients enrolled dropping out from 
the study because of side effects.
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CoNCLUSIoN
 Each clinical form of acne necessitates a spe-
cific treatment, which should redress all four major 
pathogenic factors, as recommended by a recent 
therapeutic algorithm (2,6,7). Combination thera-
py is the treatment of choice and should be initi-
ated as early as possible to simultaneously attack 
two or more of the pathogenic factors. Antibiotics 
are an affective treatment for inflammatory acne 
lesions because of their anti-inflammatory and 
anti-microbial properties. Azithromycin has many 
advantages when compared to other antimicro-
bials used in acne treatment. This study focused 
especially on the use of antibiotics in acne ther-
apy and examined the efficacy, safety and com-
pliance of 500 mg oral azithromycin given thrice 
weekly over a 12-week period. This antibiotic was 













Figure 2. Average Acne Quality of Life (AQoL) in 
46 patients
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Spring is time for Nivea cream and Nivea oil; year 1936.
(from the collection of Mr. Zlatko Puntijar)
